Next, we tested cabozantinib (CB), a TKI that targets VEGF receptors (VEGFRs), MET, AXL, TIE-2, RET and other RTKs involved in tumor development and progression through angiogenesis, invasiveness, metastasis, anti-apoptosis and drug resistance [19]. The gene discussed is RET; the disease is neoplasm.